PMID- 18485119
OWN - NLM
STAT- MEDLINE
DCOM- 20090820
LR  - 20131121
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
VI  - 69
IP  - 5
DP  - 2008 Nov
TI  - Effect of treatment with depot somatostatin analogue octreotide on primary 
      hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
PG  - 756-62
LID - 10.1111/j.1365-2265.2008.03301.x [doi]
AB  - BACKGROUND: In patients with multiple endocrine neoplasia type 1 (MEN1), 
      expression of somatostatin receptor (SST) in parathyroid adenomas and 
      effectiveness of therapy with somatostatin analogues on primary 
      hyperparathyroidism (PHP) have been scarcely investigated. OBJECTIVE: To evaluate 
      the effects of depot long acting octreotide (OCT-LAR) in patients with 
      MEN1-related PHP. PATIENTS: Eight patients with a genetically confirmed MEN1, 
      presenting both PHP and duodeno-pancreatic neuroendocrine tumours (NET), were 
      enrolled. DESIGN: The initial treatment was OCT-LAR 30 mg every 4 weeks. This 
      therapy was established to stabilize the duodeno-pancreatic NET before to perform 
      parathyroidectomy for PHP. Before OCT-LAR therapy, a SST scintigraphy was 
      performed in all patients. SST subtype 2A immunohistochemistry was performed on 
      parathyroid tumour samples from three patients undergone parathyroidectomy after 
      OCT-LAR therapy. MEASUREMENTS: Serum concentrations of PTH, calcium and 
      phosphorus as well as the 24-h urine calcium : creatinine ratio and the renal 
      threshold phosphate concentration were evaluated before and after OCT-LAR. 
      RESULTS: After OCT-LAR therapy, hypercalcaemia and hypercalciuria normalized in 
      75% and 62.5% of patients, respectively, and serum phosphorus and renal threshold 
      phosphate significantly increased. Serum PTH concentrations significantly 
      decreased in all patients and normalized in two of them. SST subtype 2A 
      immunostaining was found in all parathyroid adenomas investigated, while SST 
      scintigraphy showed a positive parathyroid tumour uptake in three of eight 
      patients (37.5%). CONCLUSION: Six months of OCT-LAR therapy controlled 
      hypercalcaemia and hypercalciuria in two-thirds of patients with MEN1-related 
      PHP. Direct OCT-LAR effects mediated by binding to SST expression on parathyroid 
      tumour cells are likely the main mechanism to explain the activity of this 
      compound on calcium and phosphorus abnormalities in MEN1 PHP.
FAU - Faggiano, Antongiulio
AU  - Faggiano A
AD  - Department of Molecular and Clinical Endocrinology and Oncology, Federico II 
      University of Naples, Naples, Italy. afaggian@unina.it
FAU - Tavares, Lidice Brandao
AU  - Tavares LB
FAU - Tauchmanova, Libuse
AU  - Tauchmanova L
FAU - Milone, Francesco
AU  - Milone F
FAU - Mansueto, Gelsomina
AU  - Mansueto G
FAU - Ramundo, Valeria
AU  - Ramundo V
FAU - De Caro, Maria Laura Del Basso
AU  - De Caro ML
FAU - Lombardi, Gaetano
AU  - Lombardi G
FAU - De Rosa, Gaetano
AU  - De Rosa G
FAU - Colao, Annamaria
AU  - Colao A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20080514
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Delayed-Action Preparations)
RN  - 51110-01-1 (Somatostatin)
RN  - RWM8CCW8GP (Octreotide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents, Hormonal/administration & dosage/pharmacology
MH  - Delayed-Action Preparations
MH  - Drug Administration Schedule
MH  - Duodenal Neoplasms/*drug therapy
MH  - Female
MH  - Humans
MH  - Hyperparathyroidism, Primary/*complications/drug therapy/surgery
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/complications/*drug therapy
MH  - Neuroendocrine Tumors/*drug therapy
MH  - Octreotide/*administration & dosage/pharmacology
MH  - Pancreatic Neoplasms/*drug therapy
MH  - Parathyroidectomy
MH  - Somatostatin/analogs & derivatives
MH  - Young Adult
EDAT- 2008/05/20 09:00
MHDA- 2009/08/21 09:00
CRDT- 2008/05/20 09:00
PHST- 2008/05/20 09:00 [pubmed]
PHST- 2009/08/21 09:00 [medline]
PHST- 2008/05/20 09:00 [entrez]
AID - CEN3301 [pii]
AID - 10.1111/j.1365-2265.2008.03301.x [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2008 Nov;69(5):756-62. doi: 
      10.1111/j.1365-2265.2008.03301.x. Epub 2008 May 14.